Glenmark Pharmaceuticals said on Friday that its subsidiary Glenmark Generics has entered into a settlement and licence agreement with US-based Nycomed to resolve patent infringement lawsuit for fluticasone propionate lotion, used for treating skin pain and itch.
“Glenmark Generics Ltd has entered into a settlement and licence agreement with Nycomed US to resolve the patent infringement suit regarding Glenmark's abbreviated new drug application for Fluticasone Propionate 0.05 lotion,” Glenmark said in a filing to the Bombay stock Exchange.
“Under the terms of agreement, Glenmark will be able to market and distribute its Fluticasone Propionate lotion under a royalty-bearing license from Nycomed US in March 2012, or earlier in certain circumstances,” it added.